A Single-Centre Prospective Phase 0 Translational Study for Predicting Response of High Grade Serous Ovarian Cancers to Paclitaxel Chemotherapy
While paclitaxel is very effective in killing cancer cells in a proportion of patients, some
patients don't respond to this treatment. As with any chemotherapy, paclitaxel is associated
with unpleasant side effects. We are doing this study to try and understand what is
happening in cancer cells in different individuals after paclitaxel treatment that make them
respond differently to the same treatment. We hope that this study will enable us to develop
a method to identify women who are suitable for this form of treatment. We also want to
understand why some cancer cells don't get killed with paclitaxel. This information will
help us to select treatment to suit an individual patient, and thus improve the outcome of
treatment and avoid giving treatment that will not benefit the patient.
Observational
Observational Model: Case-Only, Time Perspective: Prospective
Correlation between βIII tubulin expression and Mitotic Index (MI) following single agent paclitaxel treatment
Correlation between βIII tubulin expression and Mitotic Index (MI) before and after single agent paclitaxel treatment to determine whether overexpression of βIII tubulin is associated with Paclitaxel resistance
Before and 24-hours after paclitaxel treatment
No
United Kingdom: Research Ethics Committee
OXO-PCR-01
NCT01770535
November 2012
June 2015
Name | Location |
---|